View source for Endocyte

{{short description|American pharmaceutical company}}
{{Infobox company
| name = Endocyte
| native_name = <!-- Company's name in home country language -->
| native_name_lang = <!-- Use ISO 639-2 code, e.g. "fr" for French. If there is more than one native name, in different languages, enter those names using {{tl|lang}}, instead. -->
| trading_name = <!-- d/b/a/, doing business as - if different from legal name above -->
| logo =
| type = [[Subsidiary]]
| traded_as = {{NASDAQ was|ECYT}}
| predecessor =
| successor =
| founder =
| defunct = <!-- {{End date|YYYY|MM|DD}} -->
| fate =
| area_served =
| key_people = Mike Sherman ([[President (corporate title)|president]] and [[Chief executive officer|CEO]])
| industry = [[Biologic medical product|Biopharmaceutical]]
| genre = <!-- Only used with media and publishing companies -->
| products =
| production =
| services =
| revenue =
| operating_income =
| net_income =
| aum = <!-- Only used with financial services companies -->
| assets =
| equity =
| num_employees = 78
| parent = [[Novartis]]
| divisions =
| subsid =
| homepage = {{URL|https://www.endocyte.com}}
| footnotes =
| intl =
| caption =
| romanized =
| former type =
| foundation = {{Start date and age|1996}}
| location_city = West Lafayette, Indiana
| location_country = United States
| locations = <!-- Number of locations, stores, offices &c. -->
| bodystyle =
}}
'''Endocyte''' is a [[Biologic medical product|biopharmaceutical]] company established in 1996 and headquartered in [[West Lafayette, Indiana]],<ref name=genengnews2013>{{cite journal |last1=Potera |first1=Carol |title=Exploiting Folate Pathways to Treat Cancer: Endocyte Uses an Imaging Agent to Select Patients Likely to Respond to Its Therapies |journal=Genetic Engineering & Biotechnology News |date=April 2013 |volume=33 |issue=7 |pages=12, 14 |doi=10.1089/gen.33.7.03 }}</ref> a resident of the [[Purdue Research Park]].<ref name=genengnews2009>{{Citation
|title=Clinical Trials Update |year=2009 |author=<!--Staff--> |journal=[[Genetic Engineering & Biotechnology News]] |page=58 |volume=29 |issue=8 }}</ref>  In 2011 the company completed successfully an [[initial public offering]] (IPO).<ref>{{cite news |last1=Rapaport |first1=Lisa |last2=Spears |first2=Lee |title=Drugmaker Endocyte Rises 29% After Initial Public Offering |url=https://www.bloomberg.com/news/articles/2011-02-03/cancer-drug-developer-endocyte-drops-price-for-initial-public-offering |work=Bloomberg |date=4 February 2011 }}</ref> {{As of|2013}}, the company had 93 employees.<ref name=genengnews2013/>  The original [[President (corporate title)|president]] and [[Chief Executive Officer|CEO]], Ron Ellis<!--no wikipedia article as of June 2013-->,<ref name=genengnews2013/> was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by [[Novartis]].<ref>{{Cite web |last=Taylor |first=Nick Paul |date=2018-10-18 |title=Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push |url=https://www.fiercebiotech.com/biotech/novartis-inks-2-1b-endocyte-buyout-furthering-radiotherapy-push |access-date=2022-04-13 |website=Fierce Biotech |language=en}}</ref>
Endocyte is advancing the first technology platform for the creation of [[small molecule drug conjugate]]s (''a.k.a.'' SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD).<ref name=genengnews2013/><ref>{{cite web|url=http://www.fiercedrugdelivery.com/story/endocytes-kidney-conjugates-get-right-spot/2012-08-08|title=Endocyte's kidney conjugates get right to the spot - FiercePharma|website=www.fiercedrugdelivery.com}}</ref>
Endocyte’s lead drug candidate is [[vintafolide]], an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by [[Merck & Co.|Merck]] for $120 million in an upfront payment and up to $880 million in milestone payments.<ref name="reuters.com">{{cite news |title=Endocyte soars on cancer drug deal with Merck |url=https://www.reuters.com/article/us-merck-idUSBRE83F0W120120416 |work=Reuters |date=16 April 2012 }}</ref>
Vintafolide is a [[small molecule drug conjugate]] consisting of a small molecule targeting the [[folate receptor]], which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of [[vinblastine]].<ref name=genengnews2013/>  Endocyte retained rights to the development and commercialization of [[etarfolatide]].<ref name="reuters.com"/>
Endocyte’s other preclinical drug candidates also target the [[folate receptor]] as well as [[glutamate carboxypeptidase II|prostate-specific membrane antigen]] (PSMA) receptors.<ref name=genengnews2013/>
The company was formed based on technology developed by Philip Low<!--no wikipedia article as of June 2013--> (the company's [[Chief science officer|CSO]]), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system,<ref name=genengnews2013/> referred to now as [[folate targeting]].<ref>{{cite journal |last1=Leamon |first1=C. P. |last2=Low |first2=P. S. |title=Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. |journal=Proceedings of the National Academy of Sciences |date=1 July 1991 |volume=88 |issue=13 |pages=5572–5576 |doi=10.1073/pnas.88.13.5572 |pmid=2062838 |pmc=51919 |bibcode=1991PNAS...88.5572L |doi-access=free }}</ref> The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets,  such as [[glutamate carboxypeptidase II|prostate-specific membrane antigen]] (PSMA) and has also developed, with [[Bristol-Myers Squibb]], an [[epothilone]]-folic acid conjugate (BMS-753493), described at a 2008 conference.<ref name=covello2008>{{cite journal |last1=Covello |first1=Kelly |last2=Flefleh |first2=Christine |last3=Menard |first3=Krista |last4=Wiebesiek |first4=Amy |last5=McGlinchey |first5=Kelly |last6=Wen |first6=MeiLi |last7=Westhouse |first7=Richard |last8=Reddy |first8=Joe |last9=Vlahov |first9=Iontcho |last10=Hunt |first10=John |last11=Rose |first11=William |last12=Leamon |first12=Chris |last13=Vite |first13=Greg |last14=Lee |first14=Francis |title=Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development |journal=Cancer Research |date=1 May 2008 |volume=68 |issue=9 Supplement |pages=2326 |url=https://cancerres.aacrjournals.org/content/68/9_Supplement/2326 }}</ref>
In mid-October 2018, [[Novartis]] announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.<ref>{{cite news |title=Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash |url=https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |archive-url=https://web.archive.org/web/20181128212657/https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |url-status=dead |archive-date=November 28, 2018 |work=Reuters |date=18 October 2018 }}</ref><ref>{{cite news |last1=Miller |first1=John |title=Novartis pushes deeper into nuclear medicine with $2.1 billion deal |url=https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |archive-url=https://web.archive.org/web/20181128211658/https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |url-status=dead |archive-date=November 28, 2018 |work=Reuters |date=18 October 2018 }}</ref> Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate [[Lutetium (177Lu) vipivotide tetraxetan|<sup>177</sup>Lu-PSMA-617]] being targeted against metastatic castration-resistant prostate cancer.<ref>{{cite web|url=https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms|title=Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms|website=Novartis}}</ref>
==References==
{{reflist|2}}
==External links==
* {{official||https://www.endocyte.com}}
{{Finance links historical
| name = Edocyte
| sec_cik = 0001235007
}}
{{authority control}}
[[Category:1996 establishments in Indiana]]
[[Category:Pharmaceutical companies established in 1996]]
[[Category:West Lafayette, Indiana]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Health care companies based in Indiana]]
[[Category:Companies formerly listed on the Nasdaq]]
[[Category:2011 initial public offerings]]
[[Category:2018 mergers and acquisitions]]
[[Category:American subsidiaries of foreign companies]]
[[Category:Novartis]]